SGHT Sight Sciences, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1531177 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.2%
TTM net income YoY38.4%
TTM EPS YoY42.2%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—
Margins
Gross margin87.7%
Operating margin-29.5%
Net margin-32.1%
FCF margin-19.1%
EBITDA margin-29.1%
Returns
ROE-50.1%
ROA-25.7%
ROIC (approx.)-166.6%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets53.2%
Debt / equity0.83x
Current ratio5.04x
Interest coverage-5.06x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $77.36M | $79.87M |
| Cost of revenue | $10.70M | $11.58M |
| Gross profit | $66.67M | $68.28M |
| R&D expense | $14.61M | $17.99M |
| SG&A expense | $89.16M | $100.83M |
| Operating income | -$37.10M | -$50.53M |
| Interest expense | $5.14M | $4.66M |
| Pretax income | -$38.42M | -$51.27M |
| Income tax | $10,000 | $236,000 |
| Net income | -$38.43M | -$51.51M |
| EBITDA | -$36.61M | -$49.82M |
| EPS (basic) | -0.74 | -1.03 |
| EPS (diluted) | -0.74 | -1.03 |
| Weighted avg. shares (diluted) | 52.15M | 50.13M |
| Balance sheet | ||
| Cash & equivalents | $91.97M | $120.36M |
| Receivables | $9.74M | $10.79M |
| Inventory | $7.77M | $6.33M |
| Current assets | $112.73M | $139.77M |
| PP&E, net | $1.61M | $1.58M |
| Total assets | $115.30M | $142.84M |
| Current liabilities | $11.03M | $15.47M |
| Short-term debt | $0 | $0 |
| Long-term debt | $40.30M | $39.36M |
| Total debt | $40.30M | $39.36M |
| Total liabilities | $51.36M | $55.32M |
| Shareholders' equity | $63.94M | $87.52M |
| Net debt | -$51.66M | -$81.00M |
| Shares outstanding | 53.49M | 50.94M |
| Cash flow statement | ||
| Operating cash flow | -$29.69M | -$22.35M |
| Capital expenditure | $224,000 | $385,000 |
| Free cash flow | -$29.92M | -$22.74M |
| Investing cash flow | -$224,000 | -$385,000 |
| Financing cash flow | $1.79M | $4.96M |
| Depreciation & amortization | $487,000 | $712,000 |
| Stock-based compensation | $13.05M | $17.08M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.